Introduction
============

Lung cancer is the leading cause of cancer-related death throughout the world, while 80%--85% of primary lung cancer cases are specifically non-small cell lung cancer (NSCLC).[@b1-ott-6-1315] The prognosis of NSCLC cases is usually poor because of late diagnosis and therapeutic limitations. Therefore, exploration of new molecular markers involved in progression of NSCLC can facilitate effective targeted treatment and prognostic assessment. Based on advancement of the knowledge about the molecular mechanisms of NSCLC, much interest has focused recently on an aberrant MET signaling pathway in NSCLC.

MET, which is encoded by the *MET* gene, is the receptor with the highest affinity for hepatocyte growth factor/scatter factor. Hepatocyte growth factor/scatter factor binds to the MET receptor and results in autophosphorylation of several tyrosine residues within the intracellular region, leading to activation of downstream signaling pathways, such as phosphoinositide-3-kinase (PI3K), Ras-Rac/Rho, Ras mitogen-activated protein kinase, and phospholipase C-γ.[@b2-ott-6-1315] Thus, the activated hepatocyte growth factor/MET pathway promotes tumor growth, angiogenesis, and metastasis in several types of human cancers, including NSCLC, making it a promising research target for potential anticancer treatment.[@b3-ott-6-1315]--[@b6-ott-6-1315]

MET abnormalities occur frequently in NSCLC, including protein overexpression, gene mutation, and gene amplification. Although several clinical studies have revealed that MET protein is expressed in approximately 70% of adenocarcinoma and 40% of squamous cell carcinoma in lung cancer cases and overexpression of MET is associated with a poor prognosis in NSCLC patients, the clinicopathologic features and prognostic value of MET overexpression remains controversial.[@b7-ott-6-1315]--[@b9-ott-6-1315]

One of the tumorigenic mechanisms responsible for development of NSCLC is evasion of apoptosis.[@b10-ott-6-1315] Defects in regulation of apoptosis lead to tumorigenesis and resistance to chemotherapy in various cancer cells.[@b11-ott-6-1315],[@b12-ott-6-1315] Alterations in proapoptotic and antiapoptotic pathways are common in cancer cells, and regulation of apoptosis is a complicated process that involves a myriad of proteins.[@b13-ott-6-1315] In particular, BAD, one of the death-promoting proteins in the Bcl-2 gene family, exerts its death-promoting effect by heterodimerizing with BCL-X~L~ and BCL-2 death antagonists in the mitochondria, and is tightly regulated by survival factors.[@b14-ott-6-1315] Dephosphorylation activates BAD protein to initiate apoptosis, while phosphorylation of several serine residues (Ser-112 and Ser-136) will inactivate BAD to promote cell survival.[@b15-ott-6-1315] Although phosphorylation of BAD has been shown to contribute to tumorigenesis and drug resistance, the clinical relevance and prognostic value of phospho-BAD protein expression in NSCLC remains unclear. Furthermore, studies have recently presented evidence that AKT, a serine/threonine protein kinase downstream of PI3K, can bind to and phosphorylate BAD at Ser-136 residues in vitro.[@b16-ott-6-1315],[@b17-ott-6-1315] Thus, activated hepatocyte growth factor/MET signaling may be linked to phosphorylation of BAD at the Ser-136 residual through the PI3K-AKT pathway and play a key role in regulation of cell survival in NSCLC. However, a combined analysis of MET and phospho-BAD abnormalities in NSCLC has never been reported, and this new insight of combining biomarkers might improve the clinical outcome of NSCLC.

In this study, we detected the expression of MET and phospho-BAD(Ser-136) using immunohistochemistry and Western blotting, and explored whether the expression level of MET correlated with phospho-BAD(Ser-136) in these patients. We also investigated their clinicopathologic and prognostic significance in NSCLC.

Patients and methods
====================

Study population
----------------

One hundred and eighty-three NSCLC patients who underwent tumor resection at the First Affiliated Hospital of Xi'an Jiaotong University from 2003 to 2010 were enrolled in the study. The patients included 141 males and 42 females aged 44--71 (mean 56.2) years. None of these patients received neoadjuvant chemotherapy before surgery. All patients were followed closely until June 30, 2012, and the mean duration of follow-up was 39.2 ± 12.6 months. Tumor histologic classification and differentiation were done according to the 1999 histologic classification standards of lung cancer published by the World Health Organization. TNM staging was carried out according to the 2004 guidelines of the National Comprehensive Cancer Network for NSCLC. Clinical and pathologic features of the patients enrolled in the study are shown in [Table 1](#t1-ott-6-1315){ref-type="table"}. The research was approved by the institutional ethics committee of First Affiliated Hospital of Medical College of Xi'an Jiaotong University. Written informed consent was obtained from each patient.

Immunohistochemistry
--------------------

First, formalin-fixed and paraffin-embedded tissue sections (4 μm) underwent deparaffinization and hydration. Antigen retrieval was done in buffer (1 mmol/L EDTA/phosphate-buffered saline, pH 9.0) at 98°C for 30 minutes in a water bath. Endogenous peroxide blocking was performed with 3% hydrogen peroxide for 10 minutes. Next, the slides were incubated with rabbit anti-MET antibody (1:200; Santa Cruz Biotechnology Inc, CA, USA) and rabbit antiphospho-BAD(Ser-136) antibody (1:200; Abcam, Cambridge, MA, USA) overnight at 4°C. The stained sections were exposed to a 3,3-diaminobenzidine kit (Zhongshan Biotechnology Inc, Beijing, People's Republic of China) and finally counterstained with Mayer's hematoxylin. An irrelevant rabbit antiserum instead of primary antibodies served as the negative control.

Immunohistochemical analysis
----------------------------

The results of staining were evaluated by two independent pathologists who were blinded to the clinical data. Immunochemical scoring was based on both the percentage of positive cells and the intensity of staining on five randomly visual fields under the optical microscope. The intensity of staining was scored as: 0, without stain; 1, straw yellow; 2, brown; and 3, dark brown. According to the percentage of tumor cells stained positive, extent of staining was scored as: 0, 0%; 1, 1%--25%; 2, 26%--50%; 3, 51%--75%; or 4, 76%--100%. The final score was the sum of the two scores. Tumor tissues with a final score ≤3 were considered as negative, while those with a final score \>3 were considered as positive.

Western blot analysis
---------------------

An immunoblot assay was done on 12 cases that were assessed by immunohistochemistry and considered to be representative staining examples of MET and phospho-BAD(Ser-136) expression. Total protein was extracted from the fresh frozen tissues using a whole protein extraction kit (KeyGEN, Nanjing, People's Republic of China) according to the manufacturer's instructions. Concentration of protein were determined by using the BCA Protein Assay Reagent (Thermo Scientific, Rockford, IL, USA). Equal amounts of total protein from different samples were electrophoresed on a 10% sodium dodecyl sulfate-polyacrylamide gel and transferred to nitrocellulose membrane using standard protocols. Rabbit anti-MET (1:200; Santa Cruz Biotechnology Inc), rabbit antiphospho-BAD(Ser-136) (1:200; Abcam) and rabbit anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 1:3000; Proteintech Group, Chicago, IL, USA) antibodies and secondary antibody (1:5000; Cell Signaling Technology, Beverly, MA, USA) were used to detect MET, phospho-BAD(Ser-136), and GAPDH proteins, respectively. Proteins were detected by enhanced chemiluminescence (Thermo Scientific).

Statistical analysis
--------------------

Statistical Package for the Social Sciences version 17.0 software (SPSS Inc, Chicago, IL, USA) was used for the statistical analysis. The association between clinical characteristics and MET and phospho-BAD(Ser-136) expression status was determined using the Chi-squared (χ^2^) test. Spearman's rank correlation analysis was used to analyze the association between MET and phospho-BAD(Ser-136) expression levels. Overall survival curves were calculated using the Kaplan--Meier method and compared by log-rank test. Multivariate analysis was performed using a Cox proportional hazards regression model analysis. A value of *P* \< 0.05 was considered to be statistically significant.

Results
=======

Expression of MET and phospho-BaD(ser-136) in NSCLC by immunohistochemistry and their association with clinicopathologic variables
----------------------------------------------------------------------------------------------------------------------------------

In this study, the aberrant expression of MET and phospho-BAD(Ser-136) in NSCLC tissue specimens was first evaluated by immunohistochemical analysis. MET protein was primarily localized in the cytoplasm or on the cell membrane of tumor cells, while phospho-BAD(Ser-136) protein was found predominantly in the cytoplasm ([Figures 1](#f1-ott-6-1315){ref-type="fig"} and [2](#f2-ott-6-1315){ref-type="fig"}). Immunohistochemical staining analysis showed that MET was expressed in 67.2% (123/183) of these NSCLC cases, including 60 adenocarcinomas and 63 squamous cell carcinomas. Phospho-BAD(Ser-136) was expressed in 49.2% (90/183) of these NSCLC cases, including 42 adenocarcinomas and 48 squamous cell carcinomas. However, neither MET nor phospho-BAD(Ser-136) protein was associated with any clinicopathologic characteristics, including sex, age, smoking history, histology, differentiation, T-status, lymph node metastasis, or TNM stage. Detailed results are shown in [Table 1](#t1-ott-6-1315){ref-type="table"}.

Association of MET expression level with phospho-BAD(Ser-136) expression in NSCLC by immunohistochemistry and Western blotting
------------------------------------------------------------------------------------------------------------------------------

We next investigated the association between MET expression and phospho-BAD(Ser-136) expression in NSCLC by immunohistochemistry, and found there was a significant association between MET and phospho-BAD(Ser-136) expression levels ([Table 2](#t2-ott-6-1315){ref-type="table"}, Spearman's *r* = 0.268, *P* \< 0.001). Of the 123 tumor tissues with MET-positive expression, 72 cases (72/123, 58.5%) also displayed phospho-BAD(Ser-136)-positive expression. According to the expression status of MET and phospho-BAD(Ser-136), all NSCLC patients were classified into two groups, ie, MET+/phospho-BAD(Ser-136)+ (39.3%, 72/183) and others (60.7%, 111/183). The correlation between the MET+/phospho-BAD(Ser-136)+ phenotype and clinicopathologic variables was also analyzed, as shown in [Table 1](#t1-ott-6-1315){ref-type="table"}.

To confirm that MET expression was significantly associated with phospho-BAD(Ser-136) expression, as determined by immunohistochemistry, protein from frozen tissues of 12 representative examples of MET and phospho-BAD(Ser-136) staining was extracted. Western blotting analysis showed that high levels of phospho-BAD(Ser-136) were observed only in the samples with high expression of MET by immunohistochemistry, while phospho-BAD(Ser-136) was correspondingly downregulated in all the samples with low expression of MET by immunohistochemistry ([Figures 1](#f1-ott-6-1315){ref-type="fig"} and [2](#f2-ott-6-1315){ref-type="fig"}).

Survival analysis
-----------------

The correlations between MET and phospho-BAD(Ser-136) expression level and prognosis in NSCLC patients were analyzed by the Kaplan--Meier method. As shown in [Figure 3](#f3-ott-6-1315){ref-type="fig"} and [Table 3](#t3-ott-6-1315){ref-type="table"}, patients with MET-positive expression had a poor prognosis in NSCLC (*P* \< 0.001; [Figure 3A](#f3-ott-6-1315){ref-type="fig"}). The median survival time for MET-positive and MET-negative expression was 38.9 and 60.3 months, respectively. However, expression of phospho-BAD(Ser-136) was not significantly associated with overall survival (*P* = 0.310; [Figure 3B](#f3-ott-6-1315){ref-type="fig"}). When considering overall survival and combined status of MET and phospho-BAD(Ser-136) expression, we found that the MET+/phospho-BAD(Ser-136)+ phenotype was associated with shorter overall survival than the others (*P* \< 0.001; [Figure 3C](#f3-ott-6-1315){ref-type="fig"}).

Next, to test whether MET expression was an independent prognostic factor in NSCLC patients, we performed a multivariate survival analysis. Although in univariate analysis, T-status (*P* = 0.031), TNM stage (*P* = 0.001), and MET expression (*P* \< 0.001), as well as combined expression status of MET+/phospho-BAD(Ser-136)+ (*P* \< 0.001) were associated with overall survival, in multivariate analysis, only expression of MET protein (hazard ratio 4.321, 95% confidence interval 2.508--7.446, *P* = 0.001), and TNM stage (hazard ratio 2.276, 95% confidence interval 1.305--3.967, *P* \< 0.004) were independent prognostic factors in our NSCLC patients. Detailed data are shown in [Tables 3](#t3-ott-6-1315){ref-type="table"} and [4](#t4-ott-6-1315){ref-type="table"}.

Discussion
==========

In this study, we analyzed the expression of MET and phospho-BAD(Ser-136) in NSCLC for the first time. MET and phospho-BAD(Ser-136) proteins were expressed in 67.2% and 49.2% of the study population of NSCLC patients, respectively, and there was a significant association between MET and phospho-BAD(Ser-136) expression levels on both immunohistochemistry and Western blotting. MET overexpression was associated with poor survival and was an independent indicator of the prognosis, whereas expression of phospho-BAD(Ser-136) was not associated with overall survival.

MET, a high-affinity receptor for hepatocyte growth factor, is usually considered as an oncogene.[@b18-ott-6-1315] Hepatocyte growth factor binds to MET receptor and undergoes phosphorylation on intracellular tyrosine residues, leading to activation of some downstream signaling events. The hepatocyte growth factor/MET pathway has multiple biological functions, including cell proliferation, motility, angiogenesis, and morphogenesis. Although many human cancers show overexpression of MET, the role of MET overexpression in the development and progression of NSCLC is not fully understood. In NSCLC, MET protein is reported to be overexpressed in tumor tissues relative to adjacent tissues, and expression rates range between 24.0% and 81.0%.[@b19-ott-6-1315]--[@b22-ott-6-1315] In the current study, MET expression positivity was observed in 67.2% (123/183) of resected NSCLC tissues, within the range of expression rates previously reported, but was not associated with any clinicopathologic characteristics, including sex, age, smoking history, histology, differentiation, T-status, lymph node metastasis, or TNM stage. Some clinical studies have shown that MET expression occurs more commonly in adenocarcinoma of the lung than in squamous cell carcinoma.[@b7-ott-6-1315],[@b19-ott-6-1315],[@b22-ott-6-1315] However, consistent with our study, Masuya et al detected MET protein in 188 NSCLC patients by immunohistochemistry and also failed to show any association between positivity of MET expression and histology.[@b20-ott-6-1315]

Although some studies have confirmed that overexpression of MET is associated with poor survival, the prognostic value of MET expression in NSCLC is debatable. The study reported by Masuya et al showed shortened overall survival in cases with MET-positive expression.[@b20-ott-6-1315] Similarly, Ichimura et al analyzed MET expression in 104 NSCLCs using immunohistochemistry and demonstrated a tendency for worse survival in patients with MET-positive expression.[@b7-ott-6-1315] Consistent with these data, our study showed that MET-positive expression was associated with poor overall survival in patients with NSCLC. Further, multivariate analysis revealed MET-positive expression to be an adverse prognostic factor that did not correlate with any clinicopathologic characteristics, but the clinical sequence by which MET overexpression leads to poor prognosis remains unclear. Recently, MET overexpression has been reported to contribute to development of acquired chemoresistance and radioresistance via multiple downstream pathways in several types of cancer cells.[@b23-ott-6-1315]--[@b26-ott-6-1315] Thus, MET might be involved in chemoresistance or radioresistance in NSCLC and linked to a poor prognosis. In contrast, Tsuta et al and Dziadziuszko et al reported that expression of MET protein was not associated with survival.[@b22-ott-6-1315],[@b27-ott-6-1315] The discrepancy may be due to different patient populations, antibodies, methods used, or even different scoring systems.

BAD is a distant member of the BCL-2 family (critical regulators of cell death in mammalian cells). The function of this proapoptotic molecule is regulated by phosphorylation of two sites, Ser-112 and Ser-136, which is mediated by the serine/threonine protein kinase Akt-1/PKB, downstream of PI3K.[@b28-ott-6-1315] Phosphorylation at either site results in loss of the ability of BAD to heterodimerize with the survival proteins, BCL-XL or BCL-2. Further research has shown that BAD abnormalities contribute to tumorigenesis and resistance to chemotherapy in some malignancies. Ranger et al showed that BAD-deficient mice are prone to develop leukemia/lymphoma.[@b12-ott-6-1315] Gilmore et al found that a primary culture of BAD-/-mammary cancer cells was no longer sensitive to gefitinib-induced apoptosis.[@b11-ott-6-1315] Huang et al reported that the BAD expression level decreased significantly in NSCLC, and loss of BAD independently predicted a poor prognosis, especially in smokers.[@b29-ott-6-1315] BAD was also observed to be a prognostic variable for stage II and III colon cancer and breast cancer patients.[@b30-ott-6-1315],[@b31-ott-6-1315] However, few reported studies have assessed the clinical relevance and prognostic value of phospho-BAD(Ser-136) expression.

The present study found that phospho-BAD(Ser-136) expression was not associated with any clinicopathologic characteristics. Interestingly, our study found that phospho-BAD(Ser-136) expression was significantly associated with MET expression by immunohistochemistry. Moreover, Western blotting in 12 representative NSCLC tissues confirmed increased phospho-BAD(Ser-136) detection only in cases with a high level of MET expression, while phospho-BAD(Ser-136) was correspondingly downregulated in all cases with a low level of MET expression. These data indicate that MET overexpression could upregulate expression of phospho-BAD(Ser-136), although the underlying molecular mechanism remains to be clarified. MET-associated downstream pathways, such as PI3K/AKT, may be responsible.

Although the median survival time for patients with positive phospho-BAD(Ser-136) expression (43 months) was shorter than for patients with negative phospho-BAD(Ser-136) expression (49 months), there was no significant association between the expression level of phospho-BAD(Ser-136) and overall survival. Similarly, Cartron et al detected phospho-BAD(Ser-136) in glioblastoma multiforme tumors using Western blotting and enzyme-linked immunosorbent assay and found no association between the expression level of phospho-BAD(Ser-136) and overall survival.[@b32-ott-6-1315] A possible reason for this may be the presence of many other factors affecting apoptosis in NSCLC.

The present study shows that the expression level of MET is significantly correlated with that of phospho-BAD(Ser-136) and is a negative prognostic factor in multivariate analysis. We investigated the correlation between the combined status of MET and phospho-BAD(Ser-136) expression and overall survival and found that patients with the MET+/phospho-BAD(Ser-136)+ phenotype had poorer overall survival than others at the univariate level. However, this was not an independent prognostic factor in multivariate analysis. This may be because a number of signaling pathways are activated by MET in the progression of NSCLC, except for the MET/phospho-BAD(Ser-136) pathway. Therefore, the current data indicate that MET/phospho-BAD(Ser-136) pathway might play a role in the progression of NSCLC, but not necessarily a dominant one. Further research using a larger sample size is warranted to confirm our data.

Overall, the current study suggests that there is a significant positive correlation between expression of MET and that of phospho-BAD(Ser-136). MET overexpression was shown to be an adverse prognostic marker for patients with NSCLC. Therefore, an activated MET/phospho-BAD(Ser-136) pathway might play a role in the development and progression of NSCLC.
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![Immunohistochemical staining and Western blotting for MET and phospho-BAD(Ser-136) in squamous cell carcinoma of the lung. (**A** and **B**) Positive and negative staining of MET in squamous cell carcinoma. Case 21 shows strong cytoplasmic/membrane staining, whereas case 9 shows only weak cytoplasmic staining. (**C** and **D**) Positive and negative staining of phospho-BAD(Ser-136) in squamous cell carcinoma. Case 21 shows strong cytoplasmic staining, whereas case 9 shows only weak cytoplasmic staining. (**E**) Western blotting with MET and phospho-BAD(Ser-136) expression in cases with squamous cell carcinoma of the lung, indicating increased phospho-BAD(Ser-136) detection in the case with positive expression of MET by immunohistochemistry. Magnification ×400.](ott-6-1315Fig1){#f1-ott-6-1315}

![Immunohistochemical staining and Western blotting for MET and phospho-BAD(Ser-136) in adenocarcinoma of the lung. (**A** and **B**) Positive and negative staining of MET in adenocarcinoma. Case 14 shows strong cytoplasmic/membrane staining, whereas case 26 shows only weak cytoplasmic staining. (**C** and **D**) Positive and negative staining of phospho-BAD(Ser-136) in adenocarcinoma. Case 14 shows strong cytoplasmic staining, whereas case 26 shows only weak cytoplasmic staining. (**E**) Western blotting with MET and phospho-BAD(Ser-136) expression in cases with adenocarcinoma of the lung, indicating increased phospho-BAD(Ser-136) detection in the case with positive expression of MET by immunohistochemistry. Magnification ×400.](ott-6-1315Fig2){#f2-ott-6-1315}

![Kaplan--Meier survival analysis. (**A**) Overall survival curves for patients with MET-positive and MET-negative expression (*P* \< 0.001). (**B**) Overall survival curves for patients with phospho-BAD(Ser-136)-positive and phospho-BAD(Ser-136)-negative expression (*P* = 0.310). (**C**) Overall survival curves for patients with MET+/phospho-BaD(Ser-136)+ and other phenotypes (*P* \< 0.001).](ott-6-1315Fig3){#f3-ott-6-1315}

###### 

Association between MET and pBAD^S136^ expression and combined status of MET/pBAD^S136^ and clinicopathologic parameters

  Variables                All   MET protein expression   pBAD^S136^ protein expression   MET expression/pBAD^S136^ expression                                                            
  ------------------------ ----- ------------------------ ------------------------------- -------------------------------------- ----------- ----------- ------- ----------- ------------ -------
  All                      183   60 (32.8)                123 (67.2)                                                             93 (50.8)   90 (49.2)           72 (39.3)   111 (60.7)   
  Sex                                                                                                                                                                                     
   Male                    141   48 (34.0)                93 (66.0)                       0.634                                  75 (53.2)   66 (46.8)   0.317   51 (36.2)   90 (63.8)    0.153
   Female                  42    12 (28.6)                30 (71.4)                                                              18 (42.9)   24 (57.1)           21 (50.0)   21 (50.0)    
  Age (years)                                                                                                                                                                             
   \<60                    118   36 (30.5)                82 (69.5)                       0.471                                  63 (53.4)   55 (46.6)   0.434   46 (39.0)   72 (61.0)    1.000
   ≥60                     65    24 (36.9)                41 (63.1)                                                              30 (46.2)   35 (53.8)           26 (40.0)   39 (60.0)    
  Smoking history                                                                                                                                                                         
   Yes                     117   39 (33.3)                78 (66.7)                       0.964                                  57 (48.7)   60 (51.3)   0.546   45 (38.5)   72 (61.5)    0.867
   No                      66    21 (31.8)                45 (68.2)                                                              36 (54.5)   30 (45.5)           27 (40.9)   39 (59.1)    
  Histology                                                                                                                                                                               
   AC                      84    24 (28.6)                60 (71.4)                       0.337                                  42 (50.0)   42 (50.0)   0.955   36 (42.9)   48 (57.1)    0.457
   SCC                     99    36 (36.4)                63 (63.6)                                                              51 (51.5)   48 (48.5)           36 (36.4)   63 (63.6)    
  Differentiation                                                                                                                                                                         
   Well differentiated     119   42 (35.3)                77 (64.7)                       0.412                                  60 (50.4)   59 (49.6)   1.000   47 (39.5)   72 (60.5)    1.000
   Poorly differentiated   64    18 (28.1)                46 (71.9)                                                              33 (51.6)   31 (48.4)           25 (39.1)   39 (60.9)    
  T-status                                                                                                                                                                                
   T1-2                    144   45 (31.3)                99 (68.7)                       0.510                                  75 (52.1)   69 (47.9)   0.634   57 (39.6)   87 (60.4)    1.000
   T3-4                    39    15 (38.5)                24 (61.5)                                                              18 (46.2)   21 (53.8)           15 (38.5)   24 (61.5)    
  Lymph node metastasis                                                                                                                                                                   
   No                      142   47 (33.1)                95 (66.9)                       1.000                                  71 (50.0)   71 (50.0)   0.814   59 (41.5)   83 (58.5)    0.340
   Yes                     41    13 (31.7)                28 (68.3)                                                              22 (53.7)   19 (46.3)           13 (31.7)   28 (68.3)    
  TNM stage                                                                                                                                                                               
   I + II                  135   48 (35.6)                87 (64.4)                       0.246                                  69 (51.1)   66 (48.9)   1.000   54 (40.0)   81 (60.0)    0.895
   III + IV                48    12 (25.0)                36 (75.0)                                                              24 (50.0)   24 (50.0)           18 (62.5)   30 (37.5)    

**Abbreviations:** pBAD^S136^, phospho-BAD(ser-136); AC, adenocarcinoma; SCC, squamous cell carcinoma; TNM, tumor-node-metastasis.

###### 

Association between MET and pBAD^S136^ expression in non-small cell lung cancer tissues

  Variable      Total   pBAD^S136^ protein                
  ------------- ------- -------------------- ---- ------- ---------
  MET protein                                     0.268   \<0.001
   Negative     60      42                   18           
   Positive     123     51                   72           

**Abbreviation:** pBAD^S136^, phospho-BAD(Ser-136).

###### 

Univariate analysis of clinicopathologic variables for overall survival

  Variables                              Total   Overall survival   *P*              
  -------------------------------------- ------- ------------------ ---------------- ---------
  Sex                                                                                
   Male                                  141     46.725 ± 1.827     43.145--50.305   0.836
   Female                                42      49.064 ± 4.641     39.967--58.161   
  Age (years)                                                                        
   \<60                                  118     45.019 ± 2.041     41.020--49.019   0.112
   ≥60                                   65      52.389 ± 3.549     45.433--59.344   
  Smoking history                                                                    
   Yes                                   117     46.381 ± 2.212     42.045--50.716   0.627
   No                                    66      48.333 ± 2.806     42.832--53.833   
  Histology                                                                          
   AC                                    84      45.265 ± 2.795     39.786--50.743   0.424
   SCC                                   99      48.254 ± 2.256     43.832--52.677   
  Differentiation                                                                    
   Well differentiated                   119     49.118 ± 2.199     44.809--53.428   0.084
   Poorly differentiated                 64      40.759 ± 1.874     37.086--44.432   
  T-status                                                                           
   T1-2                                  144     48.539 ± 1.946     44.725--52.353   0.031
   T3-4                                  39      38.546 ± 2.591     33.467--43.624   
  Lymph node metastasis                                                              
   No                                    142     46.687 ± 1.915     42.934--50.439   0.745
   Yes                                   41      44.818 ± 2.613     36.695--49.940   
  TNM stage                                                                          
   I + II                                135     49.005 ± 1.913     45.256--52.754   0.001
   III + IV                              48      34.520 ± 1.999     30.602--38.438   
  MET expression                                                                     
   Negative                              60      60.289 ± 2.967     54.475--66.104   \<0.001
   Positive                              123     38.889 ± 1.371     36.202--41.577   
  pBAD^S136^ expression                                                              
   Negative                              93      48.510 ± 2.237     44.126--52.894   0.310
   Positive                              90      42.972 ± 2.043     38.967--46.977   
  MET expression/pBAD^S136^ expression                                               
   MET+/pBaD^S136^+                      72      37.856 ± 1.812     34.305--41.407   \<0.001
   Others                                111     50.739 ± 2.145     46.534--54.944   

**Abbreviations:** AC, adenocarcinoma; SCC, squamous cell carcinoma; TNM, tumor-node-metastasis; pBAD^S136^, phospho-BAD(Ser-136).

###### 

Multivariate analysis of clinicopathologic variables for overall survival

  Variables                   Overall survival   *P*            
  --------------------------- ------------------ -------------- ---------
  TNM stage                                                     
   III + IV versus I + II     2.276              1.305--3.967   0.004
  MET expression                                                
   Positive versus negative   4.321              2.508--7.446   \<0.001

**Abbreviations:** CI, confidence interval; TNM, tumor-node-metastasis.
